Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, today announces an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 has the potential to transform the treatment of IPF and restore lung function. The disease is currently considered to be incurable and inevitably progressive.
- C21 continues to be safe and well tolerated with no treatment-related serious adverse events
- C21 continues to demonstrate long-term efficacy, at 36 weeks the average FVC had increased to +350 mL over baseline, which is +530 mL over the expected trajectory of untreated patients (n= 19; p=0.001)
- The data will be orally presented at the American Thoracic Society (ATS) international congress on May 21st and during a webcast on May 26th, including a Q&A session
- Vicore plans to progress clinical development of C21 through initiation of a phase 2b trial (ANDAS) and will conclude recruitment to the AIR trial